Procter & Gamble will sell the rights to its osteoporosis drug Actonel (risedronate) in Japan to Ajinomoto for $210 million, the Japanese company announced.
Currently, Ajinomoto produces Actonel under a licence from Procter & Gamble, and Eisai is responsible for distribution. Sales of risedronate in Japan were estimated to be approximately 30 billion yen ($317 million) during the previous fiscal year, according to Ajinomoto.
To read more Top Story articles, click here.
